Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics.
Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution), formerly known as Brimochol PF, achieves effect after around 30 minutes and lasts for up to 10 hours, according to Tenpoint. It is the first dual-agent eye drop approved for the treatment of presbyopia and the fourth topical treatment approved overall, following Vuity (pilocarpine HCl ophthalmic solution 1.25%, AbbVie), Qlosi